novartis_rm_logo_pos_rgb.png
AAA_Logo_Final_RGB (no background).png
PSMA617_PLUVICTO®_RGB_EU_300dpi.png
pngfind.com-equilateral-triangle-png-646645.png

PLUVICTO® and PSMA:
A new therapeutic option for eligible mCRPC patients

Tuesday 25 October 2022 | 18:00 – 19:00 BST

This promotional webinar is organised and funded by Advanced Accelerator Applications, a Novartis company, and is intended for GB Healthcare Professionals only.

UK | October 2022 | AAA-PSMA-UK-0065

Your attendance at the event is governed by our Healthcare Professional Event Attendance Terms. By attending the event, you are agreeing to be bound by such terms.

Adverse events should be reported. Reporting forms and information can be found at  https://yellowcard.mhra.gov.uk (UK).

Adverse events should also be reported to Novartis via  uk.patientsafety@novartis.com or online through the pharmacovigilance intake (PVI) tool at  www.report.novartis.com

If you have a question about a product, please contact Medical Information on 01276 698370 or by email at  medinfo.uk@novartis.com

 

Pluvicto is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy or who are not medically suitable for taxanes.